Amid concerns over rising pharmaceutical prices, HHS finalized a rule threatening fines against drugmakers that knowingly overcharge hospitals and providers under the 340B drug discount program.

Issued by the Health Resources and Services Administration, the rule includes civil penalties of up to $5,000 for each time a 340B provider paid a manufacturer more than the established ceiling price for a single drug product, regardless of the number of units purchased. This includes any order placed directly with a manufacturer, or through a wholesaler, authorized distributor or agent.

The rule will be enforced by the HHS inspector general’s office, on a case-by-case basis, beginning April 1.